Clinical trialNCT02764541Active, not recruitingPhase 2Interventional

Palbociclib and Endocrine Therapy for LObular Breast Cancer Preoperative Study (PELOPS)

SponsorDana-Farber Cancer InstituteEnrollment195Breast Cancer

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This research study is evaluating how well Breast Cancer responds to preoperative treatment with Endocrine treatment in combination with a drug called Palbociclib or Endocrine treatment alone as possible treatments for Hormone Receptor Positive Breast Cancer.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Otto Metzger, MD
Dana-Farber Cancer Institute
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

11 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Stamford Hospital
Stamford, Connecticut, United States
Eastern Maine Medical Center
Brewer, Maine, United States
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
Dana-Farber at St. Elizabeth'S Medical Center
Boston, Massachusetts, United States
Df/bwcc at Milford Regional Medical Center
Milford, Massachusetts, United States
Df/bwcc in Clinical Affiliation With South Shore Hospital
South Weymouth, Massachusetts, United States
Lifespan
Providence, Rhode Island, United States
Sarah Cannon Research Institute
Nashville, Tennessee, United States
Vanderbilt University Medical Center
Nashville, Tennessee, United States
Md Anderson Cancer Center
Houston, Texas, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Endocrine TherapyLetrozole →Palbociclib →Tamoxifen →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 24 May 2016
Primary completion: 28 Feb 2022
Completion: 30 Apr 2031
Last update posted: 23 Jun 2026
Registered enrollment: 195
Registry id: NCT02764541

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.